R&D at the cutting edge
As a research-driven enterprise, Chiesi Group invests almost 15% of turnover in research and development in our main therapy areas: respiratory, neonatal, inflammatory and rare diseases.
This passionate commitment to innovation in terms of both active ingredients and new formulations is yielding record results, with patents being filed at a rate of one or more every working day (in 2008) and an exceptionally promising pipeline of potential new medicines.
A world class new research hub
An exciting addition to our research facilities in Italy, France, the UK and the USA is a large new state-of-the-art research hub nearing completion in Chiesi’s birthplace of Parma.
Equipped with all the skills and technologies needed for identifying lead compounds, preclinical and clinical development and managing regulatory activities and our worldwide R&D portfolio, this sustainable, energy-efficient new facility will coordinate operations at our other international research sites in Chippenham (new drug delivery platforms), Paris (clinical research) and Rockville in Maryland (clinical and regulatory activities).